<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20159">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02844465</url>
  </required_header>
  <id_info>
    <org_study_id>CS-05000</org_study_id>
    <nct_id>NCT02844465</nct_id>
  </id_info>
  <brief_title>Stereotactic Laser Ablation for Temporal Lobe Epilepsy</brief_title>
  <acronym>SLATE</acronym>
  <official_title>Stereotactic Laser Ablation for Temporal Lobe Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Navigation, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Surgical Technologies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to evaluate the safety and efficacy of the Visualase MRI-guided laser
      ablation system for mesial temporal epilepsy (MTLE).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to evaluate the safety and efficacy of the Visualase MRI-guided
      laser ablation system for necrotization or coagulation of epileptogenic foci in patients
      with intractable mesial temporal lobe epilepsy.

      The study will include approximately 120 adult patients with drug-resistant MTLE treated at
      selected epilepsy centers across the United States. After the Visualase procedure, patients
      will be followed for 12 months and evaluated for freedom from seizures, quality of life,
      adverse events, and neuropsychological outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of qualifying adverse events</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Seizure freedom, defined as Engel Classification of Postoperative Outcome Class I</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seizure freedom compared to historical controls</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizure freedom, including subjects retreated with Visualase</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Boston Naming Test scores</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Rey Auditory Verbal Learning Test scores</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form-36 (SF-36) Health Survey scores</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life in Epilepsy (QOLIE-31) scores</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Temporal Lobe Epilepsy</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Visualase MRI-guided laser ablation procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Visualase MRI-Guided Laser Ablation</intervention_name>
    <description>All subjects will undergo MRI-guided laser ablation of the amygdala and hippocampus with the Visualase System.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Visualase System</other_name>
    <other_name>Visualase procedure</other_name>
    <other_name>Laser interstitial thermal therapy</other_name>
    <other_name>Stereotactic laser ablation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of drug-resistant mesial temporal lobe epilepsy (MTLE)

          -  If the subject has a vagus nerve stimulator (VNS), must have failed to achieve
             sustained seizure freedom with the VNS implanted for at least 6 months

          -  On stable antiepileptic drugs (AEDs) (and/or stable VNS setting, if applicable) and
             compliant with medication use

          -  An average of at least 1 complex partial or secondarily generalized seizure
             compatible with MTLE per month

          -  Seizure symptoms and/or auras compatible with MTLE

          -  Video EEG shows evidence of seizures from one temporal lobe consistent with MTLE

          -  MRI has evidence consistent with mesial temporal lobe sclerosis

          -  Willing and able to remain on stable AEDs (and stable VNS setting, if applicable) for
             12 months following the Visualase procedure

          -  Willing and able to comply with protocol requirements

        Exclusion Criteria:

          -  Unwilling or unable to sign the study informed consent form

          -  Pregnant or intends to become pregnant during the course of the study

          -  Currently implanted with a device contraindicating MRI

          -  Progressive brain lesions and/or tumors not associated with epileptic disease state

          -  History of previous intracranial surgery for treatment of epileptic seizures

          -  Persistent extra-temporal or predominant contralateral focal interictal spikes or
             slowing, or generalized interictal spikes on EEG

          -  Seizures with contralateral or extra-temporal ictal onset on EEG

          -  Aura and/or ictal behavior suggest an extra-temporal focus

          -  MRI evidence of epileptogenic, extra-temporal lesions or bilateral hippocampal damage

          -  If additional testing has been performed, results are discordant with the seizure
             focus scheduled for ablation

          -  Non-compliance with AED requirements

          -  IQ &lt; 70

          -  Dementia or other progressive neurological disease

          -  Unstable major psychiatric illness, psychogenic non-epileptic seizures, or medical
             illness that would contraindicate the Visualase procedure or affect the
             neuropsychological assessments

          -  Participation in other research that may potentially interfere with SLATE endpoint(s)

          -  Allergy to gadolinium
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Gross, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Sperling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guy Alvarez, PhD</last_name>
    <email>rs.slatestudy@medtronic.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Letitia Fisher</last_name>
      <phone>305-243-7108</phone>
      <email>lfisher@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Jagid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Scarpace</last_name>
      <phone>313-916-2360</phone>
      <email>LSCARPA1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Jason Schwalb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karla Crockett</last_name>
      <phone>507-538-9140</phone>
      <email>crockett.karla@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Jamie Van Gompel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Connie Lau</last_name>
      <phone>516-325-7022</phone>
      <email>clau@northwell.edu</email>
    </contact>
    <investigator>
      <last_name>Ashesh D Mehta, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liz Fletman</last_name>
      <phone>215-955-4673</phone>
      <email>elizabeth.fletman@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Sperling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 23, 2017</lastchanged_date>
  <firstreceived_date>July 15, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>epilepsy</keyword>
  <keyword>laser ablation</keyword>
  <keyword>Visualase</keyword>
  <keyword>laser interstitial thermal therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Epilepsy, Temporal Lobe</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is not a plan to share individual participant data, but aggregate data for all primary and secondary endpoints will be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
